Condensed Consolidated Interim Financial Statements Three and Nine Months Ended October 31, 2021 (Unaudited)

Notice to Reader

Under National instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed consolidated interim financial statements have been prepared by and are the responsibility of management.

The Company's independent auditor has not performed a review of these condensed consolidated interim financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of the condensed consolidated interim financial statements by an entity's auditor.

Condensed Consolidated Interim Statements of Financial Position

(Stated in Canadian Dollars)

(Unaudited)

		October 31,	January 31,
	Notes	 2021	 2021
ASSETS			
Current assets			
Cash		\$ 334,850	\$ 116,878
GST receivable		11,263	2,240
Investments	4	3,666,220	572,391
TOTAL ASSETS		\$ 4,012,333	\$ 691,509
LIABILITIES AND EQUITY			
Current liabilities			
Accounts payable and accrued liabilities		\$ 51,217	\$ 80,172
Demand loans	5	216,721	276,721
Loan payable	6	-	1,730,154
Subscriptions received in advance	7	971,501	503,501
Total current liabilities		1,239,439	2,590,548
Shareholders' Equity			
Common shares	7	6,900,198	5,131,922
Contributed surplus		260,080	220,638
Deficit		(4,387,384)	(7,251,599)
Total equity		2,772,894	(1,899,039)
TOTAL LIABILITIES AND EQUITY		\$ 4,012,333	\$ 691,509
Nature and continuance of operations	1		
Subsequent event	7		

Approved on behalf of the Board of Directors:

 "Mark Rutledge"
 "Kal Hourd"

 Mark Rutledge, Director
 Kal Hourd, Director

Condensed Consolidated Interim Statements of Earnings (Loss) and Comprehensive Earnings (Loss)

(Stated in Canadian Dollars)

(Unaudited)

		Three months ended October 31,					Nine months ended October 31,			
	Notes		2021		2020		2021		2020	
Expenses										
Filing and listing fees		\$	_	\$	1,450	\$	2,279	\$	6,950	
General and administrative		7	150	Ψ.	-,	τ.	1,370	7	-	
Management fees	8		16,350		_		64,819		_	
Professional fees			10,505		2,200		56,827		13,265	
Promotion and marketing			12,500		-,		24,958			
Share-based payments	8		39,442		-		39,442		-	
Transfer agent fees			1,574		-		13,378		-	
Loss before other items			(80,521)		(3,650)		(203,073)		(20,215)	
Other items										
Foreign exchange gain (loss)			(288)		-		1,581		-	
Finance charges	6		-		(7,180)		(10,816)		(7,180)	
Forgiveness of debt	6		-		-		32,693		-	
Fair value changes on investments	4		80,277		-		3,043,830			
Earnings (loss) and comprehensive										
earnings (loss) for the period		\$	(532)	\$	(10,830)	\$	2,864,215	\$	(27,395)	
			· · · ·	-					<u> </u>	
Basic and diluted income (loss)										
per common share	7	\$	-	\$	(0.01)	\$	0.13	\$	(0.04)	
Weighted average number of										
common shares outstanding	7		30,226,178		754,909		21,913,769		754,909	

Condensed Consolidated Interim Statements of Changes in Equity

(Stated in Canadian Dollars) (Unaudited)

	Common Shares			Contributed		
_	Number ¹		Amount	 Surplus	 Deficit	 Total
Balance at January 31, 2021	754,909	\$	5,131,922	\$ 220,638	\$ (7,251,599)	\$ (1,899,039)
Common shares issued for subsidiary	28,471,268		1,708,276	-	-	1,708,276
Common shares issued for debt	1,000,001		60,000	-	-	60,000
Share-based payments	-		-	39,442		39,442
Earnings (loss) for the period			-	-	2,864,215	2,864,215
Balance at October 31, 2021	30,226,178	\$	6,900,198	\$ 260,080	\$ (4,387,384)	\$ 2,772,894

	Commo	ares	Contributed					
	Number ¹ Amount		 Surplus Deficit			Total		
Balance at January 31, 2020 Earnings (loss) for the period	754,909 -	\$	5,131,922 -	\$ 220,638 -	\$	(7,261,923) (27,395)	\$	(1,909,363) (27,395)
Balance at October 31, 2020	754,909	\$	5,131,922	\$ 220,638	\$	(7,289,318)	\$	(1,936,758)

¹ The number of common shares reflects a one-for-ten share consolidation which occurred on April 13, 2021 (note 7). All common shares disclosed in these condensed consolidated interim financial statements reflect these changes.

Condensed Consolidated Interim Statements of Cash Flows

(Stated in Canadian Dollars) (Unaudited)

	Nine months ended Octol 2021				
Operating Activities					
Earnings (loss) for the period	\$	2,864,215	\$	(27,395)	
Items not involving cash:	Ą	2,004,213	ڔ	(27,333)	
Share-based payments		39,442	\$	_	
Finance charges		10,816	Ψ	_	
Forgiveness of debt		(32,693)		_	
Fair value changes on investments		(3,043,830)		-	
Changes in non-cash working capital items:		(-,,,			
GST receivable		(9,023)		(351)	
Accounts payable and accrued liabilities		(28,955)		17,367	
Net cash used in operating activities		(200,028)		(10,379)	
Investing Activities					
Purchase of investments		(50,000)		(1)	
Net cash provided used in investing activities		(50,000)		(1)	
Financing Activities					
Proceeds from demand loans		_		1,471,966	
Repayment of demand loans		_		(1,318,101)	
Subscriptions received in advance		468,000		-	
Net cash provided by financing activities		468,000		153,865	
Change in cash during the period		217,972		143,485	
Cash, beginning of period		116,878			
Cash, end of period	\$	334,850	\$	143,485	
Supplemental Cash Flow Information					
Income taxes paid	\$	-	\$	-	
Interest paid (received)	\$	-	\$	-	
Non-cash Financing Activities					
Issuance of common shares for purchase of subsidiary	\$	1,708,276	\$	-	
Issuance of common shares for payment of demand loans	\$	60,000	\$	-	

Notes to the Condensed Consolidated Interim Financial Statements October 31, 2021

(Stated in Canadian Dollars) (Unaudited)

1. Nature and Continuance of Operations

AJA Ventures Inc. (the "Company"), was incorporated under the laws of the Province of Alberta on April 19, 1998 and on July 26, 2002, the Company received a Certificate of Continuance from the Director under the provisions of the Canada Business Corporations Act and discontinued from the jurisdiction of Alberta. On February 11, 2020, the Company continued from under the Canada Business Corporations Act to under the Business Corporations Act (British Columbia). The Company's principal office is located at 909 – 510 Burrard Street, Vancouver, BC, V6C 3A8.

The Company's shares were previously listed on the TSX Venture Exchange ("TSX-V"), however, its shares have not traded on the TSX-V since 2009. During the nine months ended October 31, 2021, the Company voluntarily delisted its shares from the TSX-V. The Company's principal business is the identification and evaluation of assets or businesses in which to invest or acquire. To date, the Company has made equity investments in two separate life sciences businesses.

During the nine months ended October 31, 2021, the Company restructured its business by 1) completing a one-for-ten share consolidation; and 2) completing an amalgamation and shares for debt transactions (notes 3, 5, 6, and 7).

During the first quarter of calendar 2020, there was a global outbreak of a novel coronavirus identified as "COVID-19". On March 11, 2020, the World Health Organization declared a global pandemic. In order to combat the spread of COVID-19, governments worldwide have enacted emergency measures including travel bans, legally enforced or self-imposed quarantine periods, social distancing and business and organization closures. These measures have caused material disruptions to businesses, governments and other organizations resulting in an economic slowdown and increased volatility in national and global equity and commodity markets.

Central banks and governments, including Canadian federal and provincial governments, have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions. The duration and impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of any interventions. It is not possible to reliably estimate the length and severity of these developments and the impact on the financial results and condition of the Company and its operations in future periods.

These condensed consolidated interim financial statements have been prepared using accounting policies in compliance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") on the assumption that the Company will continue as a going concern and realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation.

As at October 31, 2021, the Company had not yet achieved profitable operations, has variable gains and losses depending on the valuations of its investments, and expects to incur further losses in the development of its business. These factors indicate a material uncertainty that may cast substantial doubt on the Company's ability to continue as a going concern. The Company's continuation as a going concern is primarily dependent upon its ability to raise financing from equity markets or borrowings and upon successful results from its investments. While the Company has been successful in securing financings in the past, there is no assurance that it will be able to do so in the future. Accordingly, these financial statements do not give effect to adjustments, if any, that would be necessary should the Company be unable to continue as a going concern. If the going concern assumption was not used, then the adjustments required to report the Company's assets and liabilities on a liquidation basis could be material to these financial statements.

The condensed consolidated interim financial statements are presented in Canadian dollars and all values are rounded to the nearest dollar except where otherwise indicated.

Notes to the Condensed Consolidated Interim Financial Statements October 31, 2021

(Stated in Canadian Dollars) (Unaudited)

2. Basis of Preparation

a) Statement of compliance

These condensed consolidated interim financial statements, including comparatives, are unaudited and have been prepared in accordance with IAS 34, *Interim Financial Reporting* ("IAS 34") using accounting policies consistent with the International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") and Interpretations of the International Financial Reporting Interpretations Committee ("IFRIC").

b) Basis of presentation

These condensed consolidated interim financial statements have been prepared on the basis of accounting policies and methods of computation consistent with those applied in the Company's January 31, 2021 annual financial statements.

The preparation of interim financial statements in conformity with IAS 34 requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates. These condensed consolidated interim financial statements do not include all of the information required for full annual financial statements. Accordingly, these condensed consolidated interim financial statements should be read in conjunction with the Company's last annual financial statements as at and for the year ended January 31, 2021 and filed on SEDAR.com.

These condensed consolidated interim financial statements, including comparatives, have been prepared on the basis of IFRS standards that are published and effective at the time of preparation.

These condensed consolidated interim financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair value.

These condensed consolidated interim financial statements include the accounts of the following entities:

			Location of
	<u>Relationship</u>	<u>Percentage</u>	<u>Incorporation</u>
AJA Ventures Inc.	Parent		Canada
1250148 BC Ltd.	Subsidiary	100%	Canada

Inter-company balances and transactions have been eliminated on consolidation.

c) Approval of the financial statements

The condensed consolidated interim financial statements of the Company for the three and nine months ended October 31, 2021 were reviewed by the audit committee and approved and authorized for issue by the Board of Directors on December 16, 2021.

Notes to the Condensed Consolidated Interim Financial Statements October 31, 2021

(Stated in Canadian Dollars) (Unaudited)

3. Amalgamation and Acquisition of Subsidiary

On April 19, 2021, the Company acquired a wholly-owned subsidiary, 1250148 BC Ltd., via completion of a three-cornered amalgamation (the "Amalgamation Agreement") whereby the Company incorporated a subsidiary, 1299337 BC Ltd. ("Subco") for the sole purpose of amalgamating Subco with 1250148 BC Ltd. ("Finco"). Subco and Finco were continued as one corporation ("Amalco") wholly owned by the Company. This Amalgamation Agreement was completed by the following steps:

- i) Each Finco shareholder received one common share of the Company for each Finco common share held;
- ii) Each issued and outstanding Subco common share was cancelled and replaced by one Amalco common share; and
- iii) Amalco issued one Amalco common share to the Company for each Company common share issued to the Finco shareholders.

Amalco continued under the name of 1250148 BC Ltd. The result of this transaction is the Company acquiring a 100% owned subsidiary through the issuance of 28,471,268 common shares at \$0.06 per share for \$1,708,276 (note 7). This transaction resulted in settlement of a loan payable of \$1,708,276 advanced by Finco during the year ended January 31, 2021 (note 6).

4. Investments

	 anuary 31, 2021	 Purchases	Disp	ositions	Change in Fair Value	 October 31, 2021
Cellular Goods Plc	\$ 522,390	\$ -	\$	-	\$ 3,043,830	\$ 3,566,220
Filament Ventures Corp.	50,000	-		-	-	50,000
Living Proof Institute Inc.	-	50,000		-	-	50,000
1250148 BC Ltd. (note 3)	1	-		-		_
	\$ 572,391	\$ 50,000	\$	-	\$ 3,043,830	\$ 3,666,220

a) Cellular Goods Plc ("Cellular")

Cellular is a UK based public company with a focus on establishing a premium high-quality, independently tested and compliant CBD consumer product brand. Its shares are listed and traded on the London Stock Exchange. The fair value change of \$2,963,553 represents a gain on mark-to-market of Cellular's common shares.

b) Filament Ventures Corp. ("Filament")

Filament is a Canadian based private company with a focus on being a natural psychedelic drug discovery and extraction company.

c) Living Proof Institute Inc. ("LPI")

During the three months ending October 31, 2021, the Company entered into purchase agreement (the "Agreement") to acquire LPI. Pursuant to the Agreement, the Company will acquire all of the issued and outstanding securities of LPI, on a cash-free, debt-free basis, from Dr. Sachin Patel, the owner of LPI and an arm's length party to the Company.

Notes to the Condensed Consolidated Interim Financial Statements October 31, 2021

(Stated in Canadian Dollars) (Unaudited)

4. Investments (cont'd)

In consideration, the Company will pay Dr. Patel cash consideration of \$935,000, of which \$50,000 will be paid as a non-refundable deposit (paid), and \$435,000 will be paid at closing, with the remaining cash consideration to be paid in eight equal quarterly instalments. Additionally, Dr. Patel will receive 8.25 million common shares of the Company, also to be issued in eight equal quarterly instalments, which will be subject to resale restrictions under applicable securities law. Concurrent with closing, Dr. Patel will be appointed as CEO and as a director of the Company.

LPI is a private Ontario-based functional medicine, precision wellness, and longevity focused coaching company. LPI provides coaching and consulting services to holistic healthcare practitioners all over the world. LPI's proven process radically improves practice and patient outcomes using a precision wellness approach to address metabolic health and longevity. LPI has coached over 400 functional medicine practitioners and is a pioneer in the industry. LPI has a scalable turnkey solution for practitioners to create powerful personal, patient, and practice transformation.

Completion of the acquisition is subject to numerous conditions, including the Company completing an equity financing for gross proceeds of at least \$1.0 million, and obtaining a listing of its common shares on the Canadian Securities Exchange. There is no assurance or guarantee that the Company will be able to complete the acquisition as described, or at all.

5. Demand Loans

Demand loans relate to debts incurred by the Company in prior years. The demand loans are unsecured and are due on demand. During the nine months ended October 31, 2021, the Company issued 1,000,001 common shares to settle \$60,000 of debt (note 7 and 8).

6. Loans Payable

During the year ended January 31, 2021, a loan of \$ 1,708,276 was advanced to the Company by Finco (note 3). The loan bore interest at 3% per annum, calculated monthly, and was payable on repayment of the loan. With the completion of the transaction discussed in note 3, the accrued interest was forgiven, and the loan is now an inter-company loan that is eliminated on consolidation.

7. Shareholders' Equity

a) Authorized:

An unlimited number of common shares with no par value.

- b) On April 13, 2021, the number of common shares outstanding were consolidated on a one-for-ten basis. This reduced the common shares outstanding from 7,549,302 to 754,909.
- c) During the nine months ended October 31, 2021, the Company issued the following common shares:
 - i) On April 19, 2021, the Company acquired all of the outstanding common shares of Finco (note 3) by issuing 28,471,268 common shares at \$0.06 per share for \$1,708,276.
 - ii) On April 19, 2021, the Company issued 1,000,001 common shares at \$0.06 per share for \$60,000 of debt settlement (note 5 and 8).

Notes to the Condensed Consolidated Interim Financial Statements October 31, 2021

(Stated in Canadian Dollars) (Unaudited)

7. Shareholders' Equity (cont'd)

d) Income (loss) per share:

	Three months ended October 31, 2021		Three months ended October 31, 2020		Nine months ended October 31, 2021		e months ended ctober 31, 2020
Numerator:		2021		2020		2021	 2020
Net income (loss)	\$	(532)	\$	(10,830)	\$ 2	2,864,215	\$ (27,395)
Denominator: Weighted average number of common shares (basic) Dilutive effect of stock options	30,	226,178 -		754,909 -	21	L,913,769 -	754,909 -
Weighted average number of common shares (diluted)	30,	226,178		754,909	21	1,913,769	754,909
Basic and diluted income (loss) per common share	\$	-	\$	(0.01)	\$	0.13	\$ (0.04)

e) Subscriptions received in advance:

As at October 31, 2021, the Company received \$971,501 (January 31, 2021 - \$503,501) in advance proceeds for unit subscriptions related to a private placement. The units were subscribed at \$ 0.09 per unit, and each unit is expected to consist of one common share and one-half of one share purchase warrant. Each whole warrant is expected to entitle the holder to acquire one additional common share at \$ 0.12 for a period of 24 months. As of the date of these condensed consolidated interim financial statements, these units have not been issued. Subsequent to October 31, 2021, the Company received a further \$25,000 in advance proceeds and closed the private placement by issuing 11,488,906 units at \$0.09 per unit for proceeds of \$1,034,001. Included in the 11,488,906 units were 416,667 units issued for services rendered of \$37,500.

Subsequent to October 31, 2021, the Company received \$895,004 in advance proceeds for share subscriptions related to a new private placement. This new private placement is priced at \$0.36 per common share.

8. Related Party Disclosures

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence. Related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. Related party transactions that are in the normal course of business and have commercial substance are measured at the exchange amount.

Notes to the Condensed Consolidated Interim Financial Statements October 31, 2021

(Stated in Canadian Dollars) (Unaudited)

8. Related Party Disclosures (cont'd)

The following is a summary of the related party transactions that occurred during the nine months ended October 31, 2021:

a) Compensation of key management personnel

The Company has determined that key management personnel consist of its Directors, the CEO and CFO.

The Company paid \$7,500 (2020 - \$nil) for management fees to its former CEO.

The Company paid \$51,300 (2020 - \$nil) for management fees to its current CEO. As at October 31, 2021, \$15,750 (2020 - \$nil) is included in accounts payable and accrued liabilities.

The Company paid \$6,019 (2020 - \$nil) for management fees to its CFO.

The Company incurred share-based payments of \$39,442 all of which represents the fair value vesting of stock options granted to key management personnel.

Key management personnel were not paid post-employment benefits, termination benefits, or other long-term benefits during these periods.

b) Other related party transactions

The Company issued 1,000,001 common shares to the former CEO of the Company for payment of \$60,000 of debts outstanding. As at October 31, 2021, the Company owes the former CEO \$nil.

At October 31, 2021, \$nil (January 31, 2021 - \$2,680) is owing to the former CFO of the Company.

9. Financial Instruments and Capital Management

The investment operations of the Company's business involve the purchase and sale of securities and, accordingly, the majority of the Company's assets are currently comprised of financial instruments. The use of financial instruments can expose the Company to several risks, including interest rate, credit, currency, liquidity and market risk. A discussion of the Company's use of financial instruments and their associated risk is provided below:

a) Fair value

The Company classifies its financial instruments using a fair value hierarchy as a framework for disclosing fair value of financial instruments based on inputs used to value the Company's investments. The hierarchy of inputs and description of inputs is described as follows:

- Level 1: fair values are based on quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2: fair values are based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices); or
- Level 3: fair values are based on inputs for the asset or liability that are not based on observable market data, which are unobservable inputs.

Notes to the Condensed Consolidated Interim Financial Statements October 31, 2021

(Stated in Canadian Dollars) (Unaudited)

9. Financial Instruments and Capital Management (cont'd)

			October	31, 2	2021	
	Notes	Level 1	Level 2		Level 3	Total
FVTPL		 _				
Cash		\$ 334,850	\$ -	\$	-	\$ 334,850
Private company shares	4	-	-		50,000	50,000
Public company shares	4	 3,566,220	-		-	3,566,220
		\$ 3,901,070	\$ -	\$	50,000	\$ 3,951,070
			January	31. 2	2021	
	Notes	 Level 1	Level 2		Level 3	Total
FVTPL			 			
Cash		\$ 116,878	\$ -	\$	-	\$ 116,878
Private company shares	4	-	-		572,391	572,391
Public company shares	4	 -	-		-	
		\$ 116,878	\$ -	\$	572,391	\$ 689,269

Fair value estimates are made at the statement of financial position date, based on relevant market information and other information about financial instruments. As at October 31, 2021, the Company's financial instruments were cash, investments, and trade and other payables. The amounts reflected in the statements of financial position for cash and trade and other payables are carrying amounts and approximate their fair values due to their short-term nature.

The fair value of unquoted investments is established using valuation techniques. These may include the use of recent arm's length transactions, a Black-Scholes option pricing model, discounted cash flow analysis, a probability-weighted expected return model, or a current value method. Where a fair value cannot be estimated reliably, the investment is reported at the carrying value at the previous reporting date.

The Company assesses at each reporting period whether there is any objective evidence that the unquoted investments are impaired. The unquoted investments are deemed to be impaired, if and only if, there is objective evidence of impairment as a result of one or more events that have occurred after the initial recognition of the asset (an incurred 'loss event') and that loss event (or events) has an impact on the estimated future fair value of the investments that can be reliably measured.

b) Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company's cash is exposed to credit risk, with the carrying value being the Company's maximum exposure. The Company's cash consists of funds held at a chartered Canadian bank and legal counsel trust accounts. The Company is required to review impairment of its financial assets at amortized costs at each reporting period and to review its allowance for doubtful accounts for expected future credit losses. The Company minimizes credit risk by performing credit reviews, ongoing credit evaluation and account monitoring procedures.

Notes to the Condensed Consolidated Interim Financial Statements October 31, 2021

(Stated in Canadian Dollars) (Unaudited)

9. Financial Instruments and Capital Management (cont'd)

c) Liquidity risk

Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company's liquidity and operating results may be adversely affected as a result of downturn in stock market conditions generally or related to matters specific to the Company, or if the value of the Company's investments declines, resulting in losses upon disposition. The Company currently generates cash flow primarily from issuances of its common shares. The Company may in the future dispose of certain investments in order to fund obligations as they become due under normal operating conditions.

d) Market risk

The Company is exposed to certain market risk that the value of, or future cash flows from, the Company's financial assets will significantly fluctuate due to changes in market prices. The value of the financial assets may be affected by changes in interest rates, foreign exchange rates, and equity and commodity prices. The Company is exposed to market risk in its investments, and unfavorable market conditions could result in dispositions of investments at less than favorable prices. Additionally, the Company is required to mark to market its FVTPL investments at the end of each reporting period. This process could result in significant write-downs of the Company's investments over one or more reporting periods, particularly during periods of overall market instability, which would have a significant unfavorable effect on the Company's financial position.

The Company's investments include public company shares. The following table shows the estimated sensitivity on the statement of earnings (loss) and comprehensive earnings (loss) for the nine-month period ended October 31, 2021 of the closing price of the Company's public company shares with all other variables held constant as at October 31, 2021:

Percentage of change	Change in earnings and comprehensive	Change in earnings and comprehensive
in closing prices	earnings from % increase in closing price	earnings from % decrease in closing price
5%	\$178,311	\$(178,297)
10%	\$356,622	\$(356,622)

e) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to significant interest rate risk as cash only comprised bank account balances as of October 31, 2021. The Company had no interest rate swaps as at or during the nine months ended October 31, 2021.

f) Currency risk

Currency risk is the risk that fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. Financial instruments that impact the Company's earnings or loss due to currency fluctuations include foreign currency denominated assets and liabilities. The Company does not use derivative instruments or hedges to manage currency risks. The sensitivity of the Company's earnings or loss due to changes in the exchange rate between the foreign currency and Canadian dollar is included in the table below:

Notes to the Condensed Consolidated Interim Financial Statements October 31, 2021

(Stated in Canadian Dollars) (Unaudited)

9. Financial Instruments and Capital Management (cont'd)

			Effect of +/-		
		10	% change in		
Currency denomination	Investments		currency		
United Kingdom	\$ 3,566,220	\$	356,622		

g) Capital management

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to identify and acquire new investments or business opportunities. The Company does not have any externally imposed capital requirements to which it is subject. The Company considers the aggregate of its cash and common shares as capital. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new common shares; issue debt; acquire or dispose of assets; or adjust the amount of cash.

Most of the Company's investments are in the early stage of development and are not producing positive cash flow. As such, the Company is dependent on external financing to fund its activities. In order to carry out operations, the Company will spend its existing working capital and raise additional amounts as needed.